Madrigal Pharmaceuticals
MDGL
132 hedge funds and large institutions have $1.36B invested in Madrigal Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 46 increasing their positions, 41 reducing their positions, and 12 closing their positions.
117% more call options, than puts
Call options by funds: $9.07M | Put options by funds: $4.18M
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
12% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 41
6% more funds holding
Funds holding: 124 → 132 (+8)
3.97% more ownership
Funds ownership: 75.37% → 79.34% (+4%)
1% less capital invested
Capital invested by funds: $1.38B → $1.36B (-$17.2M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$40.9M |
| 2 |
BlackRock
New York
|
+$35M |
| 3 |
State Street
Boston,
Massachusetts
|
+$25.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$27.8M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$27.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$14.5M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.68M |
| 5 |
Goldman Sachs
New York
|
-$5.72M |
MDGL Hedge Fund Activity: Q4 2020 in Review
132 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2020, worth a combined $1.36B — down 1.2% from $1.38B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MDGL positions and 12 closed out — a net gain of 8 holders — while 46 added to existing stakes and 41 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $40.9M. The largest seller was HealthCor Management, cutting an estimated $27.8M.
- 132 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2020, up from 124 in Q3 2020.
- Funds reported $1.36B of Madrigal Pharmaceuticals stock for Q4 2020, down 1.2% quarter-over-quarter.
- 20 funds opened new Madrigal Pharmaceuticals positions in Q4 2020 and 12 closed out, a net change of +8 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2020 was Avoro Capital Advisors, an estimated $40.9M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2020 was HealthCor Management, an estimated $27.8M sold.
Based on aggregated 13F filings for Q4 2020.